** Brokerage Stifel starts coverage on drug developer Palvella Therapeutics PVLA.O with "buy" rating and $45 PT
** New PT represents a 65% upside to the stock's last close
** Stifel thinks PVLA has the potential to build a portfolio of rare skin disease treatments, "which collectively could have multi-billion-dollar potential"
** Stifel notes co's gel QTORIN optimizes for delivery of the treatment into the deepest regions of the skin with potency and high patient tolerability
** Including session's moves, PVLA stock more than doubled YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。